Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127071701 | 12707170 | 1 | I | 20160729 | 20160823 | 20160901 | 20160901 | EXP | FR-PFIZER INC-2016399448 | PFIZER | 47.00 | YR | F | Y | 0.00000 | 20160901 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127071701 | 12707170 | 1 | PS | XANAX | ALPRAZOLAM | 1 | Oral | UNK | Y | 18276 | TABLET | ||||||||
| 127071701 | 12707170 | 2 | SS | XANAX | ALPRAZOLAM | 1 | Oral | INCREASED DOSE | Y | 18276 | TABLET | ||||||||
| 127071701 | 12707170 | 3 | SS | TAHOR | ATORVASTATIN CALCIUM | 1 | Oral | 10 MG, 1X/DAY | Y | 20702 | 10 | MG | FILM-COATED TABLET | QD | |||||
| 127071701 | 12707170 | 4 | SS | ADVAGRAF | TACROLIMUS | 1 | Oral | UNK | Y | 0 | |||||||||
| 127071701 | 12707170 | 5 | SS | ADVAGRAF | TACROLIMUS | 1 | Oral | 2.5 MG, 1X/DAY | Y | 0 | 2.5 | MG | QD | ||||||
| 127071701 | 12707170 | 6 | SS | ADVAGRAF | TACROLIMUS | 1 | Oral | UNK | Y | 0 | |||||||||
| 127071701 | 12707170 | 7 | SS | INEXIUM | ESOMEPRAZOLE | 1 | Oral | UNK | Y | 0 | FILM-COATED TABLET | ||||||||
| 127071701 | 12707170 | 8 | SS | INEXIUM | ESOMEPRAZOLE | 1 | Oral | 40 MG, 1X/DAY | Y | 0 | 40 | MG | FILM-COATED TABLET | QD | |||||
| 127071701 | 12707170 | 9 | SS | SEROPLEX | ESCITALOPRAM OXALATE | 1 | Oral | UNK | Y | 0 | |||||||||
| 127071701 | 12707170 | 10 | SS | SEROPLEX | ESCITALOPRAM OXALATE | 1 | Oral | INCREASED DOSE | Y | 0 | |||||||||
| 127071701 | 12707170 | 11 | C | BISOPROLOL | BISOPROLOL | 1 | UNK | 0 | |||||||||||
| 127071701 | 12707170 | 12 | C | TRIATEC | RAMIPRIL | 1 | UNK | 0 | |||||||||||
| 127071701 | 12707170 | 13 | C | KAYEXALATE | SODIUM POLYSTYRENE SULFONATE | 1 | UNK | 0 | |||||||||||
| 127071701 | 12707170 | 14 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127071701 | 12707170 | 1 | Anxiety |
| 127071701 | 12707170 | 3 | Cardiovascular event prophylaxis |
| 127071701 | 12707170 | 4 | Prophylaxis against transplant rejection |
| 127071701 | 12707170 | 7 | Gastrointestinal pain |
| 127071701 | 12707170 | 9 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127071701 | 12707170 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127071701 | 12707170 | Alanine aminotransferase increased | |
| 127071701 | 12707170 | Aspartate aminotransferase increased | |
| 127071701 | 12707170 | Blood alkaline phosphatase increased | |
| 127071701 | 12707170 | Cerebral ischaemia | |
| 127071701 | 12707170 | Gamma-glutamyltransferase increased | |
| 127071701 | 12707170 | Hepatitis cholestatic |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127071701 | 12707170 | 1 | 201607 | 0 | ||
| 127071701 | 12707170 | 2 | 201607 | 20160729 | 0 | |
| 127071701 | 12707170 | 3 | 20160729 | 0 | ||
| 127071701 | 12707170 | 4 | 201607 | 0 | ||
| 127071701 | 12707170 | 5 | 201607 | 20160728 | 0 | |
| 127071701 | 12707170 | 6 | 20160729 | 0 | ||
| 127071701 | 12707170 | 7 | 201607 | 0 | ||
| 127071701 | 12707170 | 8 | 201607 | 20160729 | 0 | |
| 127071701 | 12707170 | 9 | 201607 | 0 | ||
| 127071701 | 12707170 | 10 | 201607 | 20160729 | 0 |